Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 8 of the 20 sources its claims cite were checked for support.

Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron

Open access

Abstract

The iron-regulatory hormone hepcidin is induced early in infection, causing iron sequestration in macrophages and decreased plasma iron; this is proposed to limit the replication of extracellular microbes, but could also promote infection with macrophage-tropic pathogens. The mechanisms by which hepcidin and hypoferremia modulate host defense, and the spectrum of microbes affected, are poorly understood. Using mouse models, we show that hepcidin was selectively protective against siderophilic extracellular pathogens (Yersinia enterocolitica O9) by controlling non-transferrin-bound iron (NTBI) rather than iron-transferrin concentration. NTBI promoted the rapid growth of siderophilic but not nonsiderophilic bacteria in mice with either genetic or iatrogenic iron overload and in human plasma. Hepcidin or iron loading did not affect other key components of innate immunity, did not indiscriminately promote intracellular infections (Mycobacterium tuberculosis), and had no effect on extracellular nonsiderophilic Y enterocolitica O8 or Staphylococcus aureus Hepcidin analogs may be useful for treatment of siderophilic infections.

Overview

CoChat Summary

TL;DR

Hepcidin protects mice against the siderophilic extracellular pathogen *Yersinia enterocolitica* O9 by clearing non–transferrin-bound iron (NTBI), not by lowering transferrin-bound iron. Hepcidin agonists (minihepcidins) rapidly eliminate NTBI and treat NTBI-dependent infection even when started after symptoms appear.

Key findings

  • Hepcidin-1 knockout (HKO) mice had inoculum-dependent mortality after oral *Y. enterocolitica* O9, reaching 100% at 10^8 CFU by day 6, whereas wild-type mice had 0% mortality at all inocula tested. Iron-depleted HKO mice were completely protected, while iron-loaded HKO mice had 100% mortality, indicating protection depended on systemic iron availability rather than direct antimicrobial hepcidin activity.
  • Hepcidin/iron status did not alter catheter-associated *Staphylococcus aureus* infection, nonsiderophilic *Y. enterocolitica* O8 infection, or pulmonary *Mycobacterium tuberculosis* burden at 5 and 10 weeks.
  • NTBI was detectable only in iron-loaded WT and HKO mice and correlated with yersiniosis susceptibility; serum NTBI <2 µM correlated with nonlethal systemic infection, while NTBI >2 µM associated with lethal *Y. enterocolitica* O9 infection.
  • Minihepcidin PR7310 reduced serum iron and ablated NTBI, nearly eliminating bacterial dissemination; in a replicate survival experiment, all solvent-treated mice died by day 8 versus >80% survival in minihepcidin-treated mice. Delayed treatment started on day 2 or day 3 after infection yielded 100% and 70% survival by day 21, respectively.

Methods

  • Mouse models on C57BL/6 background included wild-type, hepcidin-1 knockout (HKO), LysEGFP, and HKO/LysEGFP mice. Iron depletion used a 4-ppm Fe diet for 6–8 weeks; iron loading used intraperitoneal 20 mg iron dextran. Minihepcidin treatment was 100 nmol PR7310 or solvent by intraperitoneal injection daily.
  • Infections used *Y. enterocolitica* O9 strain Ruokola/71 and O8 strain WA by oral gavage or intraperitoneal injection (10^4–10^8 CFU/mouse), bioluminescent *S. aureus* Xen36 in a catheter-associated model, and aerosol *M. tuberculosis* Erdman at 30 CFU/mouse with assessment at 5 and 10 weeks.
  • NTBI was measured by enhanced labile plasma iron (eLPI) assay. In vitro growth assays used human plasma agar with 0–60 µM ferric ammonium citrate for *Y. enterocolitica* and liquid human plasma with 0–100 µM ferric ammonium citrate, holotransferrin, or apotransferrin for *Vibrio vulnificus*. Statistics included Student t test, Mann-Whitney rank sum, 2-way ANOVA, Kaplan-Meier/log-rank, and χ2 tests.

Limitations

  • The paper states that inbred animal models are an imperfect representation of complex human conditions and that the proposed mechanisms and therapeutic applications need further testing and refinement in human clinical studies.
  • The paper states that it remains to be determined which specific forms of NTBI in circulation stimulate rapid growth of siderophilic pathogens, and that testing of additional infection models is needed to determine whether hepcidin-mediated changes in transferrin saturation control other microbes.
  • The methods state that researchers were not blinded to treatment group; evident from the text, the findings are proof-of-concept in mice and ex vivo human plasma, with no human clinical outcomes reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1182/blood-2017-03-772715

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

8 Valid · 0 Not valid · 7 Not checked · 86 Own results and interpretations

63 more claims · 1 with their cited sources checked

Create a free account to see all 101 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 5
  • It may state two separate claims as one. 28
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 33 references

Cited by

See all 145

Metadata

Authors
Stefanova, D., Raychev, A., Arezes, J., Ruchala, P., Gabayan, V., Skurnik, M., Dillon, B. J., Horwitz, M. A., Ganz, T., Bulut, Y., & Nemeth, E.
Affiliations
  • Molecular, Cellular, and Integrative Physiology Graduate Program and
  • University of California, Los Angeles (US)
  • Medical Research Council (MRC) Human Immunology Unit, MRC Weatherall Institute for Molecular Medicine, University of Oxford, Oxford, United Kingdom;
  • University of Helsinki (FI)
Corresponding author
  • Bulut, Yonca
  • Nemeth, Elizabeta
Venue
Blood
Published
2017-07-20
Volume
130
Issue
3
Pages
245-257
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2611092877
Cited by
145
References
33
Citations by year
2026: 9 · 2025: 14 · 2024: 12 · 2023: 13 · 2022: 19 · 2021: 18 · 2020: 20 · 2019: 21 · 2018: 16 · 2017: 3
FWCI
12.62
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK090554, R01DK107309)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
hepcidin, non-transferrin-bound iron, innate immunity, infection resistance, hereditary hemochromatosis, iron metabolism, iron sequestration
MeSH terms
Animals, Binding, Competitive, Disease Models, Animal, Hemochromatosis, Humans, Iron, Mice, Inbred C57BL, Mycobacterium tuberculosis, Oligopeptides, Protein Binding, Staphylococcal Infections, Staphylococcus aureus, Transferrin, Yersinia enterocolitica, Gene Expression, Survival Analysis, Mice, Knockout, Iron Overload, Mice, Catheter-Related Infections, Disease Resistance, Hepcidins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. https://app.cochat.ai/papers/10.1182/blood-2017-03-772715
The paper
Stefanova, D., Raychev, A., Arezes, J., Ruchala, P., Gabayan, V., Skurnik, M., Dillon, B. J., Horwitz, M. A., Ganz, T., Bulut, Y., & Nemeth, E. (2017). Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood. https://doi.org/10.1182/blood-2017-03-772715

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.